Abstract
Stem cell research is a promising area of biomedical research with tremendous potential for increasing our understanding of human development and for improving clinical treatment options across a range of serious conditions. However, it has historically also been a complex field, both scientifically and ethically. It raises numerous policy tensions including those related to the acceptability of different forms of research in the field and, more recently, regarding how to respond to the rapidly growing private market for clinical applications that lack broadly accepted forms of evidence of safety and efficacy. Using the Canadian market for unproven stem cell interventions as a case study, this review paper identifies questions of governance and policy options as they relate to the future of stem cell research and its clinical translation in Canada. Key areas of inquiry include the roles and influence of evidence, scientific and clinical imperatives, and public pressure on policy decisions, as well as the role of regulation in managing risks and uncertainty in fast moving fields of biomedicine. Examining these questions in a Canadian context is particularly timely at present given the emerging domestic private market for stem cell-based interventions coupled with scientific developments in the field that are highlighting ambiguities and other challenges with our current regulatory framework.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aach J, Lunshof J, Iver E, Church GM (2017) Addressing the ethical issues raised by synthetic human entities with embryo-like features. Elife 6. https://doi.org/10.7554/eLife.20674
Assisted Human Reproduction Act, S.C. 2004, c. 2
Australian Government, Department of Health. Therapeutic Goods Administration (2017) Regulation of autologous cell and tissue products; Including so called ‘autologous stem cell’ therapies. Media Release October 24, 2017. Available at: https://www.tga.gov.au/media-release/regulation-autologous-cell-and-tissue-products
Baird P (1993) Proceed with care – final report of the Royal Commission on New Reproductive Technologies. Available at: http://publications.gc.ca/site/eng/9.699855/publication.html
Barben D, Fisher E, Selin C, Guston DH (2008) Anticipatory governance of nanotechnology: foresight, engagement, and integration. In: Hackett EJ, Amsterdamska O, Lynch M, Wajcman J (eds) The handbook of science and technology studies. MIT Press, Cambridge, pp 979–1000
Bauer G, Elsallab M, Abou-El-Enein M (2018) Concise review: a comprehensive analysis of reported adverse events in patients receiving unproven stem cell-based interventions. Stem Cells Transl Med 7:676–685
Berger I, Ahmad A, Bansal A et al (2016) Global distribution of businesses marketing stem cell-based interventions. Cell Stem Cell 19:158–162
Blackwell T (2017) Canadian clinics begin offering stem-cell treatments experts call unproven, possibly unsafe. The National Post, July 3, 2017. Available at: http://nationalpost.com/news/canada/canadian-clinics-begin-offering-stem-cell-treatments-experts-call-unproven-possibly-unsafe/wcm/f73a696e-a34f-4f4f-9d92-ca8a26707a03. Accessed Sept 10, 2019
Bosley K et al (2015) CRISPR germline engineering – the community speaks. Nat Biotechnol 33(5):478–486
Brokowski C (2018) Do CRISPR germline ethics statements cut it? CRISPR J 1(2). https://doi.org/10.1089/crispr.2017.0024. Available at: https://www.liebertpub.com/doi/pdfplus/10.1089/crispr.2017.0024. Accessed Sept 10, 2019
Bubela T, Kleiderman E, Master Z, Ogbogu U, Ravitsky V, Zarzeczny A, Knoppers M (2019) Canada’s Assisted Human Reproduction Act: pragmatic reforms in support of research. Front Med 6. https://doi.org/10.3389/fmed.2019.00157
Butenko A, Larouche P (2015) Regulation for innovativeness or regulation of innovation? Law Innov Technol 7(1):52–82
Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada and Social Sciences and Humanities Research Council of Canada (2014) Tri-council policy statement: ethical conduct for research involving humans. Available at: http://www.pre.ethics.gc.ca/eng/policy-politique_tcps2-eptc2_2018.html. Accessed Sept 10, 2019
Cattapan A, Snow D (2017) Everything and nothing: regulating embryo research in Canada. New Genet Soc 36(1):43–65. https://doi.org/10.1080/14636778.2017.1289469
Caulfield T (2002) Politics, prohibitions and the lost public perspective: a comment on bill C-56: the assisted human reproduction act. Alberta Law Rev 40(2):451–463
Caulfield T, Bubela T (2007) Why a criminal ban? Analyzing the arguments against somatic cell nuclear transfer in the Canadian parliamentary debate. Am J Bioeth 2:51–61
Caulfield T, Murdoch B (2019) Regulatory and policy tools to address unproven stem cell interventions in Canada: the need for action. BMC Med Ethics 20:51. https://doi.org/10.1186/s12910-019-0388-4
Caulfield T, Rachul C, Zarzeczny A, Bubela T (2010) Stem cell research in the news: more than a moral status debate? Scr Theol 7(2):311–323
Caulfield T, Sipp D, Murry C, Daley G, Kimmelman J (2016) Confronting stem cell hype. Science 352(6287):776–777
Caulfield T, Marcon A, Murdoch B, Brown J, Tinker Perrault S, Jarry J, Snyder J, Anthony S, Brooks S, Master Z, Rachul C, Ogbogu U, Greenberg J, Zarzeczny A, Hyde-Lay R (2019) Health misinformation and the power of narrative messaging in the public sphere. Can J Bioethics 2(2):52–60
Chisholm J, von Tigerstrom B, Bedford P, Fradette J, Viswanathan S (2017) Workshop to address gaps in regulation of minimally manipulated autologous cell therapies for homologous use in Canada. Cytotherapy 19:1400–1411
Chisholm J, Ruff C, Viswanathan S (2019) Current state of Health Canada regulation for cellular and gene therapy products: potential cures on the horizon. Cytotherapy 21:686–698
Cohen IG, Adashi EY, Ravitsky V (2019) How bans on germline editing deprive patients with mitochondrial disease. Nat Biotechnol 37:589–592
College of Physicians and Surgeons of Alberta (2018) Stem cell regenerative therapy; Standards & guidelines. Available at: http://www.cpsa.ca/wp-content/uploads/2018/02/Stem-Cell-Regenerative-Therapy-Standards.pdf. Accessed Sept 4, 2019
Collier R (2012) Professionalism: the privilege and burden of self-regulation. CMAJ 184(14):1559–1560
Competition Act, R.S.C. 1985, c. C-34
Competition Bureau; Government of Canada. 2019. “Our approach”. Available at: https://www.competitionbureau.gc.ca/eic/site/cb-bc.nsf/eng/h_00149.html. Accessed Sept 9, 2019
Connolly R, O’Brien T, Flaherty G (2014) Stem cell tourism – a web-based analysis of clinical services available to international travelers. Travel Med Infect Dis 12:695–701
Cossu G, Birchall M, Brown T et al (2018) Lancet commission: stem cells and regenerative medicine. Lancet 391(10123):883–910
Crowe K (2017) Unapproved stem cell therapies on the market in Canada. CBC News. November 16, 2017. Available at: http://www.cbc.ca/news/health/stem-cell-private-clinic-health-canada-osteoarthritis-1.4401391. Accessed Sept 10, 2019
Crowe K (2018) Controversial U.S. stem cell clinics have Canadian connections. CBC News. May 12, 2018. Available at: https://www.cbc.ca/news/health/second-opinion180511-1.4659092. Accessed Sept 10, 2019
Crowe K (2019) A stem cell ‘cautionary tale’ as Health Canada cracks down on private clinics. CBC News. July 13, 2019. Available at: https://www.cbc.ca/news/health/stem-cell-canada-newfoundland-health-canada-mesenchymal-private-clinics-1.5209689. Accessed Sept 4, 2019
Daley G (2017) Polar extremes in the clinical use of stem cells. N Engl J Med 376:1075–1077
Fagotto E, Burgués V, Fung A (2019) A taxonomy to engage patients: objectives, design, and patient activation. NEJM Catalyst. Available at: https://catalyst.nejm.org/health-information-taxonomy-engage-patients/. Accessed Sept 4, 2019
Fairburn B, Fulton M, Pohler D (2015) Governance of co-operative federations: principles and a framework for research. CIA Research International Conference
Food and Drug Administration (FDA) (2017a) Statement from FDA Commissioner Scott Gottlieb, M.D. on the FDA’s new policy steps and enforcement efforts to ensure proper oversight of stem cell therapies and regenerative medicine. August 28, 2017. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm573443.htm. Accessed Jan 3, 2018
Food and Drug Administration (FDA) (2017b) Regulatory considerations for human cells, tissues, and cellular and tissue-based products: minimal manipulation and homologous use – guidance for industry and food and drug administration staff. Available at: https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM585403.pdf. Accessed Jan 3, 2018
Food and Drug Administration (FDA) (2017c) Same surgical procedure exception under 21 CFR 1271.15(b): Questions and answers regarding the scope of the exception – Guidance for industry. Available at: https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-bio-gen/documents/document/ucm419926.pdf. Accessed Jan 3, 2018
Food and Drug Administration (FDA) (2017d) FDA news release: FDA warns US Stem cell clinic of significant deviations. August 28, 2017. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm573431.htm. Accessed Feb 28, 2018
Food and Drug Administration (FDA) (2018a) Warning letter: American CryoStem corporation 1/3/18. Available at: https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm591225.htm. Accessed Feb 28, 2018
Food and Drug Administration (FDA) (2018b) FDA seeks permanent injunctions against two stem cell clinics. FDA News Release May 9, 2018. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm607257.htm. Accessed Sept 10, 2019
Food and Drugs Act, R.S.C. 1985, c. F-27
Fujita M, Hatta T, Ozeki R, Akabayashi A (2016) The current status of clinics providing private practice cell therapy in Japan. Regen Med 11(1):23–32
Gamble A (2000) Economic governance. In: Pierre J (ed) Debating governance: authority, steering, and democracy. Oxford University Press, Oxford, p 110
Government of Canada (2019) Recalls & alerts: health Canada is advising Canadians about the potential health risks associated with unauthorized cell therapy treatments such as stem cell therapy. May 15, 2019. Available at: https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2019/69974a-eng.php. Accessed Sept 4, 2019
Harmon S (2016) Modernizing biomedical regulation: foresight and values in the promotion of responsible research and innovation. J Law Biosci 3(3):680–686
Harmon S, Laurie G, Haddow G (2013) Governing risk, engaging publics and engendering trust: new horizons for law and social science? Sci Public Policy 40:25–33
Harrison SE, Sozen B, Christodoulou N, Kyprianou C, Zernicka-Goetz M (2017) Assembly of embryonic and extraembryonic stem cells to mimic embryogenesis in vitro. Science 356(6334):eaal1810. https://doi.org/10.1126/science.aal1810
Hawke B, Przybylo AR, Paciuilli D, Caulfield T, Zarzeczny A, Master Z (2019) How to peddle Hope: an analysis of YouTube patient testimonials of unproven stem cell treatments. Stem Cell Rep 12(6):1186–1189
Health Canada (2014) Prohibitions related to scientific research and clinical applications. Available at: https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/legislation-guidelines/assisted-human-reproduction/prohibitions-scientific-research-clinical-applications.html. Accessed Sept 3, 2019
Health Canada (2019) Health Canada Policy position paper – autologous cell therapy products. Available at: https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/applications-submissions/guidance-documents/cell-therapy-policy.html. Accessed Sept 4, 2019
Horner C, Tenebaum E, Sipp D, Master Z (2018) Can civil lawsuits stem the tide of direct-to-consumer marketing of unproven stem cell interventions. Regen Med 3. https://doi.org/10.1038/s41536-018-0043-6
International Society for Stem Cell Research (ISSCR) (2016) Guidelines for stem cell research and clinical translation. Available at: http://www.isscr.org/docs/default-source/all-isscr-guidelines/guidelines-2016/isscr-guidelines-for-stem-cell-research-and-clinical-translation.pdf?sfvrsn=4. Accessed Jan 3, 2018
International Society for Stem Cell Research (ISSCR) (2019) Informed consent standard for stem cell-based interventions offered outside of formal clinical trials. Available at: http://www.isscr.org/docs/default-source/policy-documents/isscr-informed-consent-standards-for-stem-cell-based-interventions.pdf. Accessed Aug 12, 2019
Isasi R, Kleiderman E, Knoppers BM (2016) Editing policy to fit the genome? Science 351(6271):337–339
Kamenova K, Caulfield T (2015) Stem cell hype: media portrayal of therapy translation. Sci Transl Med 7(278):278ps4
Kamenova K, Reshef A, Caulfield T (2014) Representations of stem cells clinics on twitter. Stem Cell Rev 10(6):753–760. https://doi.org/10.1007/s12015-014-9534-z
Klein A (2017) Jurisdiction in Canadian health law. In: Erdman J, Gruben V, Nelson E (eds) Canadian health law and policy, 5th edn. LexisNexis
Knoepfler P (2018) Update on stem cell treatment cost for 2018 from ongoing poll. The Niche; Knoepfler Lab Stem Cell Blog. Available at: https://ipscell.com/2018/04/update-on-stem-cell-treatment-cost-for-2018-from-ongoing-poll/. Accessed Sept 4, 2019
Knoppers BM, Isasi R, Caulfield T et al (2017) Human gene editing: revisiting Canadian policy. Regen Med 2. https://doi.org/10.1038/s41536-017-0007-2
Knoppers BM, Leader A, Hume S et al (2017b) Mitochondrial replacement therapy: the road to the clinic in Canada. J Obstet Gynaecol Can 39(10):916–918
Kuriyan A, AlbiniJustin TA, Townsend H et al (2017) Vision loss after intravitreal injection of autologous “stem cells” for AMD. N Engl J Med 376(11):1047–1053
Lau D, Ogbogu U, Taylor B et al (2008) Stem cell clinics online: the direct-to-consumer portrayal of stem cell medicine. Cell Stem Cell 3(6):591–594
Laurie G, Harmon S, Arzuaga F (2012) Foresighting futures: law, new technologies and the challenges of regulating for uncertainty. Law Innov Technol 4(1):1–33
Le Galès P (2011) Policy instruments and governance. In: Bevir M (ed) The SAGE handbook of governance. SAGE, London, p 2011
Levine AD, Wolf LE (2012) The roles and responsibilities of physicians in patients’ decisions about unproven stem cell therapies. J Law Med Ethics 40:122–134
Li M, Atkins H, Bubela T (2014) The global landscape of stem cell clinical trials. Regen Med 9(1). https://doi.org/10.2217/rme.13.80
Lindvall O, Hyun I (2009) Medical innovation versus stem cell tourism. Science 324:1664–1665
Master Z, Bedford P (2018) CRISPR gene editing should be allowed in Canada, but under what circumstances? JOCG 40(2):224–226
Master Z, Caulfield T (2014) Patient Booklet: What you need to know about stem cell therapies. Available at: https://oirm.ca/wp-content/uploads/2018/07/sc_patient_booklet_feb_2014.pdf. Accessed Sept 10, 2019
McLean A, Stewart C, Kerridge I (2015) Untested, unproven, and unethical: the promotion and provision of autologous stem cell therapies in Australia. Stem Cell Res Ther 6(33). https://doi.org/10.1186/scrt543
Munsie M et al (2017) Open for business: a comparative study of websites selling autologous stem cells in Australia and Japan. Regen Med 12:777–790
Murdoch B, Zarzeczny A, Caulfield T (2018) Exploiting science? A systematic analysis of complementary and alternative medicine clinic websites’ marketing of stem cell therapies. BMJ Open 8(2). https://doi.org/10.1136/bmjopen-2017-019414
Murdoch B, Rudnicki M, Caulfield T (2019) Medical colleges: tell your members to stop providing unproven stem cell therapies. Healthy Debate. Available at: https://healthydebate.ca/opinions/unproven-stem-cell-therapies. Accessed Sept 4, 2019
Ogbogu U (2013) The assisted human reproduction act reference and the thin line between health and crime. Constitutional Forum 22(1). https://doi.org/10.21991/C9RM2R
Ogbogu U (2016) Combatting unlicensed stem cell interventions through truthful advertising law: a survey of regulatory trends. McGill J Law Health 9(2):311–335
Ogbogu U, Rugg-Gunn (2008) The legal status of novel stem cell Technologies in Canada. J Int Biotechnol Law 5(5). https://doi.org/10.1515/JIBL.2008.32
Ogbogu U, Rachul C, Caulfield T (2013) Reassessing direct-to-consumer portrayals of unproven stem cell therapies: is it getting better? Regen Med 8(3):361–369
Ogbogu U, Du J, Koukio Y (2018a) The involvement of Canadian physicians in promoting and providing unproven and unapproved stem cell interventions. BMC Med Ethics 19:32. https://doi.org/10.1186/s12910-018-0273-6
Ogbogu U, Zarzeczny A, Baltz J et al (2018b) Research on human embryos and reproductive materials: revisiting Canadian law and policy. Healthcare Policy 13(3):10
Pera M, de Wert G, Dondorp W, Lovell-Badge R et al (2015) What if stem cells turn into embryos in a dish?. Nat Methods 12(10):917–919
Petersen A, Seear K, Munsie M (2013) Therapeutic journeys: the hopeful travails of stem cell tourists. Sociol Health Illn 36(5):670–685
Phillips P, Schmeiser P (2017) Science and innovation policy for the 21st century: Shaping the dialogue. JSGS policy brief series. Available at: https://www.schoolofpublicpolicy.sk.ca/research/publications/policy-brief/science-and-innovation-policy-for-the-21st-century-shaping-the-dialogue.php. Accessed Sept 10, 2019
Quay R (2010) Anticipatory governance: a tool for climate change adaptation. J Am Plan Assoc 76(4):496–511
Rachul C (2011) “What have I got to lose?”: an analysis of stem cell therapy patients’ blogs. Health Law Rev 20(1):5
Regenberg A, Hutchsinson L, Schanker B, Matthews D (2009) Medicine on the fringe: stem cell-based interventions in advance of evidence. Stem Cells 27(9):2312–2319
Robbillard J, Cabral E, Hennessey C, Kwon B, Illes J (2015) Fueling Hope: stem cells in social media. Stem Cell Rev 11(4):540–546
Rosemann A, Sleeboom-Faulkner M (2015) New regulation for clinical stem cell research in China: expected impact and challenges for implementation. Regen Med 11(1). https://doi.org/10.2217/rme.15.80
Rugg-Gunn P, Ogbogu U, Rossant J, Caulfield T (2009) The challenge of regulating rapidly changing science: stem cell legislation in Canada. Cell Stem Cell 4(4):285–288
Saraf S, Cunningham M, Kuriyan A et al (2017) Bilateral retinal detachments after intravitreal injection of adipose-derived ‘Stem Cells’ in a patient with exudative macular degeneration. Ophthalmic Surg Lasers Imaging Retina 48(9):772–775
Servick K (2016) Under 21st century cures legislation, stem cell advocates expect regulatory shortcuts. Science. December 12, 2016. Available at: http://www.sciencemag.org/news/2016/12/under-21st-century-cures-legislation-stem-cell-advocates-expect-regulatory-shortcuts-0. Accessed Sept 10, 2019
Shah S, Zettler P (2010) From a constitutional right to a policy of exceptions: abigail alliance and the future of access to experimental therapy. Yale J Health Law Policy Ethics 10:135
Shalev C (2010) Stem cell tourism – a challenge for trans-national governance. Am J Bioeth 10(5):40–42
Simmis M, Madden H, Cacciatore M, Yeo S (2016) The lure of rationality: why does the deficit model persist in science communication? Public Underst Sci 25(4):400–414
Sipp D (2011) The unregulated commercialization of stem cell treatments: a global perspective. Front Med 5(4):348–355
Sipp D, Caulfield T, Kaye J et al (2017) Marketing of unproven stem cell–based interventions: a call to action. Sci Transl Med 9(397). https://doi.org/10.1126/scitranslmed.aag0426
Sleeboom-Faulkner ME (2016) The large grey area between ‘Bona fide’ and ‘rogue’ stem cell interventions — ethical acceptability and the need to include local variability. Technol Forecast Soc Chang 109:76–86
Snyder J, Turner L, Crooks V (2018) Crowdfunding for unproven stem cell–based interventions. JAMA 319(18):1935–1936. https://doi.org/10.1001/jama.2018.3057
Sugarman J (2015) Ethics and germline gene editing. EMBO Rep 16(8):879–880
Sugarman J, Barker R, Charo RR (2019) A professional standard for informed consent for stem cell therapies. JAMA. https://doi.org/10.1001/jama.2019.11290
Thirabanjasak D, Tantiwongse K, Thorner P (2010) Angiomyeloproliferative lesions following autologous stem cell therapy. J Am Soc Nephrol 21(7):1218–1222
Turner L (2018) Direct-to-consumer marketing of stem cell interventions in Canada. Regen Med 13(6). https://doi.org/10.2217/rme-2018-0033.
Turner L, Knoepfler P (2016) Selling stem cells in the USA: assessing the direct-to-consumer industry. Cell Stem Cell 19:154–157
Vogel G (2011) Authorities shut controversial german stem cell clinic. Science May 10, 2011. Available at: http://www.sciencemag.org/news/2011/05/authorities-shut-controversial-german-stem-cell-clinic. Accessed Sept 10, 2019
von Tigerstrom B (2017) Regulating the advertising and promotion of stem cell therapies. Regen Med 12(7):815–826
Warmflash A, Sorre B, Etoc F et al (2014) A method to recapitulate early embryonic spatial patterning in human embryonic stem cells. Nat Methods 11(8):847–854. https://doi.org/10.1038/nmeth.3016
World Health Organization (WHO) (2018) Global health ethics, human genome editing. Available at: https://www.who.int/ethics/topics/human-genome-editing/en/. Accessed Sept 3, 2019
Zarzeczny A (2017) The role of regulation in healthcare – professional and institutional oversight. In: Erdman J, Gruben V, Nelson E (eds) Canadian health law and policy, 5th edn. LexisNexis
Zarzeczny A, Clark M (2014) Unproven stem cell-based interventions & physicians’ professional obligations; a qualitative study with medical regulatory authorities in Canada. BMC Med Ethics 15:75. https://doi.org/10.1186/1472-6939-15-75
Zarzeczny A, Rachul C, Nisbet M, Caulfield T (2010) Stem cell clinics in the news. Nat Biotechnol 28:1243–1246
Zarzeczny A, Caulfield T, Ogbogu U et al (2014) Professional regulation: a potentially valuable tool in responding to “stem cell tourism”. Stem Cell Rep 3(3):379–384
Zarzeczny A, Atkins H, Illes J, Kimmelman J, Master Z, Robillard JM, Snyder J, Turner L, Zettler PJ, Caulfield T (2018) The stem cell market and policy options: a call for clarity. J Law Biosci 5(3):743–758
Zettler P, Greely H (2014) The strange allure of state “right-to-try” Laws. JAMA Intern Med 174(12):1885–1886
Acknowledgements
This work was funded in part by the Stem Cell Network. Special thanks go to collaborators Ubaka Ogbogu, Barbara von Tigerstrom, Harold Atkins, Timothy Caulfield, Barbara Knoppers, Erika Kleiderman, Vardit Ravitsky, Blake Murdoch and to all participants at the Brocher Workshop (Nov 2015), the workshop on Research Aspects of the Assisted Human Reproduction Act: Time for Revision?, and the Unproven Stem Cell Procedures Workshop (Oct 2017).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Zarzeczny, A. (2019). The Future of Stem Cell Research and its Clinical Translation in Canada: Exploring Questions of Governance and Policy Options. In: Turksen, K. (eds) Cell Biology and Translational Medicine, Volume 8. Advances in Experimental Medicine and Biology(), vol 1247. Springer, Cham. https://doi.org/10.1007/5584_2019_450
Download citation
DOI: https://doi.org/10.1007/5584_2019_450
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-45892-8
Online ISBN: 978-3-030-45893-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)